Covid: Remdesivir 'has little or no effect' on survival, according to WHO margin: Calc (0.5rem / 2);

The WHO trial evaluated four potential drugs for Covid-19, including remdesivir and hydroxychloroquine.

Remdesivir was one of the first to be used for the treatment of coronavirus, and he recently gave US president, Donald Trump when he was in the hospital.

The drug maker Gilead rejected the findings of the trial.

In a statement, Gilead said the findings of the study were "incompatible" with others, and is "concerned" that the results have not yet been reviewed What did that the studio is

in its clinical trial of Solidarity, WHO tested the effects of four potential treatments -.? remdesivir an Ebola drug was one, but also looked hydroxychloroquine malaria drug, interferon drug autoimmune, and the combination of HIV drugs lopinavir and ritonavir.

dexamethasone, a low cost of steroids now widely used in patients in intensive care Covid in the UK, was not included in this study.

the four drugs were tested with 11,266 adult patients i. Total N in 500 hospitals in more than 30 countries Css-1pzprxn-BulletListContainermargin-left: 1.5rem; CSS-1pzprxn-BulletListContainer

  • What medicines can help treat coronavirus

    The results, which are to be reviewed, suggest that none of these treatments has a substantial effect on mortality or length of time spent li> EE. UU. in the hospital, the WHO said on Thursday.

    WHO said the lead scientist Swaminathan Soumya Wednesday that his judgments about hydroxychloroquine and lopinavir / ritonavir were arrested in June because they had proved ineffective. However, other trials continued.

    The results seem to contradict a previous study of this month, conducted by Gilead, which concluded that treatment with cutting remdesivir recovery time Covid for five days compared with patients who received a placebo. About 1,000 patients participated in the trial.

    What has been the reaction?

    Gilead Sciences Inc rejected findings.

    "Emergency (WHO) data appears inconsistent with stronger evidence of Multiple randomized controlled trials published in scientific journals that validate the clinical benefit of remdesivir," the company said in a statement.

    "We are concerned about the data in this open trial world has not gone through the scrutiny necessary to enable constructive scientific discussion, especially given the limitations of the trial design." copyrightReutersimage captionGilead said he was "concerned" that the study is not rated

    but Professor Martin Landray, who runs the great recovery test in the UK, said the results of the trial were 'important but sobriety '- and added that there were already concerns about the cost and accessibility of remdesivir.

    "Covid it affects millions of people and their families around the world," he added.

    "It is a rare disease. We need scalable, affordable and equitable treatment. Judgment WHO Solidarity has made the world a favor by producing clear, independent and solid results, showing once again the value of large randomized controlled trials provide the knowledge we need to face the brunt of the pandemic. "

    Remdesivir emergency use in the US Food and Drug country (FDA) was authorized on May 1. Later that month was approved for use in the UK, and has since been approved for use in several other countries. Remdesivir has been touted as a potential therapy since the beginning of the pandemic and gained further attention when the party cocktail treatments Donald Trump was formed.

    However, the WHO trial, published online, gives a damning verdict.

    There is some uncertainty in the data, but the asparagus

    Categories:
    Multipl 

    Image of How to find a teaching job in Universities in China
    Rate and Comment
    Image of 4 Ways to Spot Job Scams in China
    4 Ways to Spot Job Scams in China

    While employment opportunities are abundant in China, so are the scammers ready to take advantage of expatriates moving to the Middle Kingdom for wor

    Read more →

  • Login

     

    Register

     
    Already have an account? Login here
    loader

    contact us